검색어: rekombinantnim (슬로베니아어 - 영어)

morebitne interakcije z rekombinantnim t-pa
potential interactions with recombinant t-pa

obstajajo konsistentni dokazi, da lahko bolnikom z rakom zdravljenje z rekombinantnim humanim a
there is therefore consistent evidence to suggest that there may be significant harm to patients with cancer who are treated with recombinant human erythropoietin.

analiza učinkovitosti vključuje 6 oseb z okužbo s hcv z rekombinantnim genotipom 2/1.
the efficacy analysis includes 6 subjects with recombinant genotype 2/1 hcv infection.

analiza učinkovitosti vključuje 3 osebe z okužbo s hcv z rekombinantnim genotipom 2/1.
the efficacy analysis includes 3 subjects with recombinant genotype 2/1 hcv infection.

obstajajo konsistentni dokazi, da lahko bolnikom z rakom zdravljenje z rekombinantnim humanim eritropoetinom škoduje.
there is therefore consistent evidence to suggest that there may be significant harm to patients with cancer who are treated with recombinant human erythropoietin.

pr celotnem preživetju bolnikov, zdravljenih z rekombinantnim humanim eritropoetinom, in bolnikov v kontrolni skupini.
ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.

v odprti študiji ni bilo razlike v celotnem preživetju bolnikov, zdravljenih z rekombinantnim humanim eritropoetinom, in bolnikov v
in the four placebo-controlled studies the hazard in

v kliničnih preskušanjih so zdravilo orgalutran uporabljali skupaj z rekombinantnim folikle stimulirajočim hormonom (fsh).
in clinical trials orgalutran was used with recombinant human follicle stimulating hormone (fsh).

v odprti študiji ni bilo razlike v celokupnem preživetju med bolniki, zdravljenimi z rekombinantnim humanim eritropoetinom, in kontrolno skupino.
in the open-label study there was no difference in overall survival between patients treated with recombinant human erythropoietin and controls.

princip testa je prekinitev reakcije med rekombinantnim vp7, antigenom, vezanim na elisa ploščo, in markiranim mpt, specifičnim za vp7.
the principal of the test is the interruption of the reaction between the recombinant vp7, as the antigen bound to the elisa plate and the conjugated mab specific for the vp7.

to pomeni, da obstajajo trdni dokazi, ki kažejo, da je lahko zdravljenje z vo rekombinantnim humanim eritropoetinom zelo škodljivo za bolnike z rakom.
the extent to which these outcomes might apply to the administration of du

iz tega sledi, da obstajajo trdni dokazi, ki kažejo na to, da lahko zdravljenje z rekombinantnim humanim eritropoetinom bolnikom z rakom pomembno škoduje.
1.35, 2.06, 35 trials and 6769 patients) was observed in patients treated with recombinant human erythropoietin.

1, 35, 2, 06, 35 preskušanj in 6769 bolnikov) so opazili pri bolnikih, ki so jih zdravili z rekombinantnim humanim eritropoetinom.
1.35, 2.06, 35 trials and 6769 patients) was observed in patients treated with recombinant human erythropoietin.

v kliničnih študijah so cetrotide 3 mg uporabljali s humanim menopavznim gonadotropinom (hmg), vendar pa omejene izkušnje z rekombinantnim fsh kažejo podobno učinkovitost.
in clinical trials cetrotide 3 mg was used with human menopausal gonadotropin (hmg), however, limited experience with recombinant fsh suggested similar efficacy.

zdravilo purevax felv je cepivo z rekombinantnim poxvirusom kanarčkov (vcp97), ki vsebuje antigen virusa mačje levkemije (felv).
purevax felv is a vaccine containing feline leukaemia virus (felv) recombinant canarypox virus (vcp97).

pri bolnikih, zdravljenih z rekombinantnim humanim eritropoetinom, so ugotovili večje relativno tveganje za trombembolične dogodke (rt 1, 67, 95% iz:
an increased relative risk of thromboembolic events (rr 1.67, 95% ci:

vse bolnike, ki jih zdravimo z rekombinantnim faktorjem viii, moramo skrbno klinično nadzorovati in z ustreznimi laboratorijskimi testi spremljati morebitno nastajanje inhibitorjev (glejte tudi poglavje 4. 8).
5 recombinant coagulation factor viii should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests (see also section 4.8).

pri bolnikih, ki so se zdravili z rekombinantnim humanim eritropoetinom, so ugotovili lje zvišano relativno tveganje za tromboembolične dogodke (rr 1, 67; 95 -% iz:
an increased relative risk of thromboembolic events (rr 1.67, 95% ci: